India's pharma sector braces for impact of proposed Trump tariffs on generic drugs
AI Summary
India’s pharmaceutical sector is preparing for potential impacts from proposed Trump tariffs on generic drugs, which may disrupt global drug supply chains and increase medicine prices in the U.S., forcing strategic shifts for Indian manufacturers.
Analysts warn the levies could disrupt global drug supply chains, push up medicine prices for Americans and force Indian drugmakers to rethink their manufacturing strategies.
Politics Markets Health Commodities India pharmaceuticals Trump tariffs generic drugs supply chain medicine prices manufacturing strategies